Mural Oncology plc is a biotechnology company focused on advancing innovative treatments for cancer. The company is dedicated to developing novel therapeutic approaches by harnessing the power of immunotherapy and targeted drug delivery to improve patient outcomes. Mural Oncology aims to address significant unmet medical needs in oncology by creating treatments that enhance the body’s natural immune response and effectively target cancer cells. Through rigorous research and development, the company strives to bring transformative solutions to the market that can change the landscape of cancer therapy. Read More
Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin exploring strategic alternatives.
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.
